Loading...
Loading...
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer. Moderna Inc MRNA and Merck & Co MRK joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck’s blockbuster immunotherapy drug Keytruda.
With promising mid-stage trial results in the battle against melanoma, the duo is also conducting a late-stage study to validate their findings and expand their research scope to other types of cancer, beginning with a non-small form of lung cancer. But mRNA technology is also being used to revolutionize cancer diagnostics. Moving the needle in early cancer diagnostics.
A molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed N.V. MYNZ , today reviewed its major accomplishments from the first half of the year.
Its flagship product, colorectal cancer at-home screening test, ColoAlert is already marketed across Europe. At ASCO 2024, Mainz Biomed confirmed the results from its previous ColoFuture and eAArly DETECT studies. The pooled study was a third consecutive confirmation of the effectiveness of its tool in detecting CRC and precancerous lesions.
By integrating the Fecal Immunochemical Test .
